
Betty Iverson Retirement
November 11, 2022
After 33 years in the pharmaceutical business, our good friend and partner in Utah’s life sciences industry, Betty Iverson, is retiring from Johnson and Johnson ((J&J), effective November 11. 2022. Betty’s stellar career spans 20 years with Wyeth and 13 years with J&J. In her position as director of state government affairs at J&J, Betty has worked hand in hand with BioUtah, making significant contributions to the growth and success of Utah’s life sciences community, including building the relationships that at the end of the day, make our BioHive buzz.
In her own words, Betty puts it this way: “It has been an incredible journey and I am proud, grateful and humbled at this moment. There are so many memories, people, places and events over the years. Those who know me well understand that at the end of the day it’s the people and the relationships that matter the very most to me. As I turn this page in the story of my life know that you have made an impression and I carry you with me. I wish you so much love, peace, and happiness. I am forever grateful that our paths crossed and I know they will again.”
“Betty has touched the lives of so many in our life sciences family, on both a personal level and as part of our collective misison to improve and save lives,” said Kelvyn Cullimore, president and CEO of BioUtah. “On behalf of BioUtah, we thank Betty for her leadership over all these years and wish her all the best in her future endeavors and adventures.”
Recent News
- Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
- New Preclinical Study Demonstrates Feasibility of Microbubble-Mediated, Non-Thermal Focused Ultrasound for Brain Tumor Ablation
- Owlet Partners with Rhapsody to Connect Remote Baby Monitoring Data to EHRs
- J3 Bioscience Announces Collaboration to Study LIV-Ring VR101 for Cancer-Therapy–Related Vaginal Dryness
- 2025 BioUtah Life Sciences Awards Presented at the Mayer Brown Utah Life Sciences Summit
- PhotoPharmics Surpasses Enrollment Target with 350 Participants in First-of-a-Kind Remote, Home-Based Phase 3 “Light for PD” Clinical Trial











